FeesSafety
Pluang+

IBC cross-chain protocol donated to Linux Foundation's LF Decentralized Trust for neutral governance.

Protocol Fundamentals
10 Nov 2026, 13:56 WIB
Tokenpost
View Source
Neutral
IBC cross-chain protocol donated to Linux Foundation's LF Decentralized Trust for neutral governance.

Cosmos and the Interchain Foundation have donated the IBC cross-chain communication protocol to the Linux Foundation's LF Decentralized Trust project. This move places IBC under a neutral governance framework where multiple organizations, including Wells Fargo and Google Cloud, will collaboratively develop the protocol. The donation aims to ensure shared project ownership and coordinated advancement of blockchain interoperability technology. The hosting by LF Decentralized Trust provides a stable environment for ongoing collaborative work among diverse participants.

Cosmos and its IBC protocol donation to the Linux Foundation's LF Decentralized Trust project provide context for readers following blockchain interoperability. For readers following major cryptocurrencies on Pluang as of Nov 10, 2026 18:41 WIB, 31 of 50 major cryptocurrencies rose today. Notable movers include AVAX at Rp150.211 with a 3.13% increase and a typical hold time of 88 days, LUNC at Rp0,721 up 2.22% with a 197-day hold time and strong buy activity (79%), and SOL at Rp1.531.241 down 2.17% with a 72-day hold time and 73% sell activity.

More News

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

Manufacturers expanding Microsoft 365 Copilot must review drawing revisions and supplier permissions to prevent data breaches.

The 2026 Verizon Data Breach Investigations Report links 61% of manufacturing breaches to third parties and 81% to internal data compromise. Manufacturers adopting Microsoft 365 Copilot should carefully manage which engineering and supplier files emp...

Market News
Neutral
59 minutes ago
Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health chosen as specialty pharmacy partner for new FOP treatment Pasatru™

Soleo Health has been selected as a specialty pharmacy partner for Pasatru™ (garetosmab-grts), Regeneron's FDA-approved treatment for adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder. Pasatru™ is the first treat...

Market News
Bullish
59 minutes ago
PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera secures $25M to advance oral immunology drugs targeting TNFα and TL1A pathways.

PsiThera raised $25 million in financing led by new investors AbbVie Ventures and Lumination Capital, alongside existing backers. The funds will support development of its oral small molecule TNFα inhibitor and advance its oral TL1A inhibitors into l...

Company Fundamentals
Bullish
59 minutes ago
Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics reports Q3 2026 results, advances gene therapy trials, and extends cash runway to 2029

Opus Genetics announced its Q3 2026 financial results and significant progress in its gene therapy programs for inherited retinal diseases. Key milestones include completion of dosing in OPGx-BEST1 Cohort 2 with data expected in Q1 2027, full enrollm...

Company Fundamentals
Bullish
59 minutes ago
Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group showcases new vehicles and tech at Fenatran 2026, boosting Latin America presence.

Iveco Group is exhibiting its latest products, including new light and heavy-duty vehicles powered by FPT engines, at Fenatran 2026 in São Paulo, highlighting its strong industrial and commercial presence in Latin America. The event marks the regiona...

Market News
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App